Oxford Ledge
Search
No licensed closing price on file for CRVS. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 07:36 UTC.
This is a clinical-stage biopharmaceutical company developing drug candidates designed to modulate proteins involved in immune cell function. The company's lead candidate, soquelitinib, is designed to inhibit ITK, a protein involved in T cell signaling and activation, with potential applications in treating T cell lymphomas, inflammatory diseases like atopic dermatitis and psoriasis, and solid tumors. Soquelitinib is currently in a Phase 3 clinical trial for relapsed T cell lymphomas and a Phase 2 trial for atopic dermatitis.
Summarized from Corvus Pharmaceuticals, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗
Charts, 10-year financials, peer comparison, screening and portfolio tracking for CRVS and 5,000+ tickers.
Create a free account — keep CRVSGET /api/data?ticker=CRVS
This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt